Whalesbook
India Ki Bioeconomy Ki Toofani Chalaang!
Yaar, India ki bioeconomy ne toh sach mein dhamaal macha diya hai. Pichle saal se 18% ki tez raftaar pakad kar, yeh estimated $195 billion tak pahunch gayi hai 2025 mein. Agar aapko pata ho, toh 2014 mein yeh sirf $10 billion thi. Matlab, policy support aur naye ideas ne is sector ko ekdum badal diya hai.
Abhi sirf biopharmaceuticals hi nahi, balki biofuels, advanced enzyme solutions, digital biology aur contract research bhi iski growth mein contribute kar rahe hain.
Kahan Kahan Se Aa Raha Hai Paisa?
Is baar growth ke peeche kai bade reasons hain. Sabse pehle, 20% ethanol blending petrol mein karne ka aggressive plan chal raha hai, jisse fuel imports kam honge. Dusra, India mein diabetes aur obesity ke badhte cases ke karan GLP-1 drugs ki demand ekdum badh gayi hai.
Aur haan, Global Capability Centers (GCCs) health aur life sciences mein ek bada engine ban gaye hain. Yeh ab 300,000 se zyada Indians ko employ kar rahe hain aur global companies ke liye innovation hubs ban gaye hain. Ye sirf routine kaam nahi kar rahe, drug discovery aur digital health jaise core functions bhi handle kar rahe hain.
Biosolutions, matlab enzymes aur microbes ka use, alag-alag industries mein economic output aur sustainability ko boost kar raha hai. Bio-industrial segment, khaas kar biofuels, bhi ek bada contributor ban gaya hai.
GLP-1 Drugs Ka Boom Aur Regulatory Action
GLP-1 drugs ki badhti demand ne biopharmaceutical sector ko aur bhi fuel diya hai. India ki badi population aur badhte obesity/diabetes cases ke karan yeh ek bada market hai. Jaise hi March 2026 mein Semaglutide jaise drugs ke patents expire honge, generic aur biosimilar versions aayenge, jisse prices kam ho sakte hain aur market 2030 tak paanch guna badh sakta hai.
Lekin, is rapid growth ne regulatory body ka dhyan bhi kheench liya hai. India ke drug regulator ne misleading ads aur exaggerated claims ke khilaaf warnings jaari ki hain, jo dikhata hai ki ab is sector par scrutiny badh gayi hai.
BIRAC Ka Role Aur Future Targets
Biotechnology Industry Research Assistance Council (BIRAC) ne India ki bioeconomy ko grow karne mein bahut help ki hai. Grants, equity support aur mentorship dekar, BIRAC ne biopharma, med-tech, agri-biotech aur industrial biotech mein innovation ko badhaya hai. Isne 11,800 se zyada startups ko support kiya hai aur hazaron high-skilled jobs create kiye hain.
Dekho, targets toh bade hain: $300 billion by 2030 aur $1 trillion by 2047. Ye sab BIRAC jaise bodies ke support se hi possible ho sakta hai.
India Ka Global Stance
India ab biotech mein ek major global player ban raha hai. Top 12 biotech destinations mein se ek aur Asia Pacific mein third position par hai, global market ka lagbhag 3% hold karta hai. Ye ab India ki GDP ka 4.8% contribute karta hai.
Aage Ki Raah Aasan Nahi Hai
Lekin, $1 trillion ke target tak pahunchna itna bhi aasan nahi hai. Regulatory processes mein 18-24 mahine tak ki delays ho sakti hain, jo naye products ko market mein aane se rok sakti hain. Skill gap bhi ek bada issue hai, aur agriculture mein fragmented land holdings advanced agri-tech solutions ko scale karna mushkil bana deti hain.
Global competition bhi kafi zabardast hai. Dusre countries bhi biotech innovation mein bharpoor investment kar rahe hain. India ko sirf biosimilars par depend nahi karna chahiye, balki strong home-grown innovation par bhi focus karna chahiye. Lab discoveries ko commercial products mein badalna aur workforce mein skill gap ko fill karna bhi bahut zaroori hai.